A degradation-sensitive anionic trypsinogen (PRSS2) variant protects against chronic pancreatitisHeiko Witt, Thomas Berg, Joost P.H. Drenth et al.|Nature Genetics|2006Cited by 250
Melphalan dose in myeloma patients ≥65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry studyB. Gerber, Guido Ghilardi, Thomas Pabst et al.|Bone Marrow Transplantation|2018Cited by 20
Clinical characteristics and outcome of patients over 60 years with Hodgkin lymphoma treated in SwitzerlandAlden A. Moccia, Felicitas Hitz, Stefanie Aeppli et al.|Hematological Oncology|2020Cited by 15